- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07488832
Infusión Intravenosa de Lidocaína en Cirugía de Fusión Lumbar
Efecto de la Infusión Intravenosa Intraoperatoria de Lidocaína sobre el Consumo de Opioides Postoperatorio y la Recuperación Después de la Cirugía de Fusión Lumbar: Un Ensayo Controlado Aleatorizado
Elective lumbar fusion surgery is associated with moderate to severe postoperative pain and often requires substantial perioperative opioid administration. Excessive opioid use may lead to adverse effects such as nausea, vomiting, sedation, respiratory depression, and delayed mobilization. Intravenous lidocaine infusion has been proposed as part of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties.
This randomized, placebo-controlled clinical trial aims to evaluate the effect of intraoperative intravenous lidocaine infusion on postoperative opioid consumption and early recovery outcomes in patients undergoing elective lumbar fusion surgery. Patients will be randomly assigned to receive either intravenous lidocaine infusion or placebo during surgery.
The primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores, time to first rescue analgesic, quality of recovery, postoperative nausea and vomiting, time to mobilization, and length of hospital stay. In addition, inflammatory and oxidative stress biomarkers including interleukin-6 (IL-6) and markers of thiol-disulfide homeostasis will be measured preoperatively and postoperatively.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Lumbar fusion surgery is frequently associated with significant postoperative pain and often requires high doses of opioid analgesics during the perioperative period. Opioid administration may lead to several adverse effects including postoperative nausea and vomiting, sedation, respiratory depression, and delayed recovery. Therefore, multimodal analgesia strategies are increasingly used to improve postoperative pain control and reduce opioid requirements.
Intravenous lidocaine infusion has gained attention as an adjunct component of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties. Previous clinical studies have suggested that perioperative systemic lidocaine may reduce postoperative pain intensity, decrease opioid consumption, and improve recovery after surgery. However, evidence regarding its effectiveness in patients undergoing lumbar fusion surgery remains limited.
This prospective, randomized, placebo-controlled study will include adult patients aged 18 years or older with American Society of Anesthesiologists (ASA) physical status I-III who are scheduled for elective lumbar fusion surgery. Participants will be randomly allocated into two groups. Patients in the lidocaine group will receive an intravenous lidocaine bolus followed by continuous lidocaine infusion during surgery, whereas patients in the control group will receive an equivalent volume of normal saline infusion. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery.
All patients will receive standardized general anesthesia and postoperative multimodal analgesia. Postoperative pain will be assessed using the Numerical Rating Scale (NRS). Rescue analgesia will be administered when clinically indicated.
The primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores at predefined time points, time to first rescue analgesic requirement, postoperative nausea and vomiting incidence, quality of recovery measured by QoR-15, post-anesthesia care unit length of stay, time to mobilization, and hospital length of stay.
In addition, inflammatory and oxidative stress responses associated with surgery and lidocaine administration will be evaluated. Blood samples will be collected preoperatively and at 6 and 24 hours postoperatively to measure interleukin-6 (IL-6) levels and markers of thiol-disulfide homeostasis.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Ankara Bilkent City Hospital
- Número de teléfono: +90 312 552 6000
- Correo electrónico: ankarasehir@saglik.gov.tr
Ubicaciones de estudio
-
-
-
Ankara, Turquía (Türkiye)
- Reclutamiento
- Ankara Bilkent City Hospital
-
Contacto:
- Gokhan Erdem, MD, PhD
- Número de teléfono: 05326258766
- Correo electrónico: drgokhanerdem@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ≥18 years
- Scheduled for elective lumbar fusion surgery under general anesthesia
- American Society of Anesthesiologists (ASA) physical status I-III
- Ability to provide written informed consent
Exclusion Criteria:
- Refusal to participate in the study
- ASA physical status ≥IV
- Body mass index >35 kg/m²
- Known allergy or hypersensitivity to lidocaine or study medications
- Severe cardiac, hepatic, or renal disease
- Pregnancy
- Neurological disorders affecting pain assessment
- Chronic opioid use
- Use of opioids or antiemetic drugs before surgery
- Inability to cooperate with postoperative assessments
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Lidocaine Infusion
Patients in this group will receive continuous intravenous lidocaine infusion at a rate of 2 mg/kg/h throughout the surgical procedure following induction of general anesthesia. The infusion will be discontinued at the end of surgery. All patients will receive standardized general anesthesia and postoperative multimodal analgesia. |
Continuous intravenous lidocaine infusion will be administered during lumbar fusion surgery at a rate of 2 mg/kg/h following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery. |
|
Comparador de placebos: Placebo (Normal Saline)
Patients in this group will receive an intravenous infusion of normal saline at an equivalent rate throughout the surgical procedure following induction of general anesthesia. The infusion will be discontinued at the end of surgery. All patients will receive standardized general anesthesia and postoperative multimodal analgesia. |
An intravenous infusion of normal saline (0.9% sodium chloride) will be administered at an equivalent rate during surgery following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cumulative postoperative opioid consumption within the first 24 hours after surgery
Periodo de tiempo: 0 to 24 hours after surgery
|
Cumulative opioid consumption during the first 24 postoperative hours will be evaluated. Rescue analgesia will be administered as intravenous tramadol (100 mg) when the Numerical Rating Scale (NRS) pain score is ≥4. The cumulative tramadol dose administered during this period will be recorded in milligrams (mg). |
0 to 24 hours after surgery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Intraoperative remifentanil consumption
Periodo de tiempo: From induction of anesthesia to the end of surgery
|
Cumulative remifentanil consumption during surgery will be recorded in micrograms (µg). |
From induction of anesthesia to the end of surgery
|
|
Postoperative pain intensity
Periodo de tiempo: At arrival in the post-anesthesia care unit and at 2, 4, 6, 12, and 24 hours after surgery
|
Postoperative pain intensity will be assessed using the Numerical Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain). |
At arrival in the post-anesthesia care unit and at 2, 4, 6, 12, and 24 hours after surgery
|
|
Time to first rescue analgesic requirement
Periodo de tiempo: Within the first 24 hours after surgery
|
Time from the end of surgery to the first administration of rescue intravenous tramadol will be recorded. |
Within the first 24 hours after surgery
|
|
Quality of recovery
Periodo de tiempo: Preoperative baseline and 24 hours after surgery
|
Quality of recovery will be evaluated using the Quality of Recovery-15 (QoR-15) questionnaire, a validated patient-reported outcome measure assessing postoperative recovery. The total score ranges from 0 to 150, with higher scores indicating better postoperative recovery. |
Preoperative baseline and 24 hours after surgery
|
|
Postoperative nausea and vomiting incidence
Periodo de tiempo: 0-24 hours after surgery
|
The incidence of postoperative nausea and/or vomiting and the requirement for rescue antiemetic treatment will be recorded. |
0-24 hours after surgery
|
|
Post-anesthesia care unit length of stay
Periodo de tiempo: Immediate postoperative period (up to 24 hours after surgery)
|
Duration of stay in the post-anesthesia care unit will be recorded in minutes. |
Immediate postoperative period (up to 24 hours after surgery)
|
|
Time to mobilization
Periodo de tiempo: Up to 24 hours after surgery
|
Time from the end of surgery to the first mobilization will be recorded. |
Up to 24 hours after surgery
|
|
Serum interleukin-6 (IL-6) levels
Periodo de tiempo: Preoperatively and at 6 and 24 hours after surgery
|
Serum interleukin-6 (IL-6) levels will be measured to evaluate the inflammatory response. |
Preoperatively and at 6 and 24 hours after surgery
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Thiol-disulfide homeostasis parameters
Periodo de tiempo: Preoperatively and at 6 and 24 hours after surgery
|
Native thiol, total thiol, and disulfide levels will be measured to evaluate oxidative stress and thiol-disulfide homeostasis. |
Preoperatively and at 6 and 24 hours after surgery
|
|
Length of hospital stay
Periodo de tiempo: Through hospital discharge, an average of 5 days
|
Total duration of hospitalization will be recorded in days. |
Through hospital discharge, an average of 5 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Gokhan Erdem, MD, PhD, Department of Anesthesiology and Reanimation, Ankara Bilkent City Hospital, Ankara, Turkey
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Dolor
- Manifestaciones neurológicas
- Complicaciones Postoperatorias
- Procesos Patológicos
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Dolor Postoperatorio
- Químicos orgánicos
- Preparaciones farmacéuticas
- Aniluros
- Amidas
- Compuestos anilina
- Amina
- Acetanilidas
- Soluciones cristaloides
- Soluciones isotónicas
- Soluciones
- Lidocaína
- Solución salina
Otros números de identificación del estudio
- LidocaineInfusion
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
No plan to share individual participant data.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .